Head-to-head · Cost-Efficiency Index
Heva Health vs Medro
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Heva Health
Shoppers who want a concierge lab-panel-plus-GLP-1 bundle and can confirm their state isn't one of tirzepatide's five exclusions.
Visit Heva HealthMedro
Shoppers who will commit to a longer plan to unlock Medro's lowest published tier.
Visit MedroThe verdict
Heva Health and Medro tie on the Cost-Efficiency Index at 60/100, so neither wins outright on the numbers. For most shoppers we'd start with Heva Health (ranked #249, a hair above #253) — Shoppers who want a concierge lab-panel-plus-GLP-1 bundle and can confirm their state isn't one of tirzepatide's five exclusions. But Medro is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Heva Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Heva Health | Medro |
|---|---|---|
| Cost-Efficiency Index | 60/100 | 60/100 |
| Semaglutide / mo | $150/mo (starting dose, compounded) | $199/mo (compounded) |
| Tirzepatide / mo | $339/mo (compounded) | $299/mo (compounded) |
| Semaglutide / yr (modeled) | $1,800 | $2,388 |
| Tirzepatide / yr (modeled) | $4,068 | $3,588 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #249 | #253 |
Heva Health
60/100Where the value is
- Tirzepatide pricing is broken out into a clear, labeled ladder ($339/mo month-to-month down to $299/mo on a 6-month plan) rather than a single vague 'starting at' figure
- Explicitly discloses a real state-level restriction for tirzepatide (unavailable in Alaska, Arkansas, Indiana, Minnesota, South Carolina) instead of a vague coverage claim
- Named, credentialed care team (Dr. Caroline Tade NMD, Kasey Horrell PA-C, Dr. Daniel Hall DNP/NP-C, Kelly Moore FNP)
The tradeoffs
- The $149.99/month 'Weight Loss Program' figure is never explicitly confirmed as the semaglutide-specific price on the pages checked — it may be a generic teaser rather than a labeled per-drug rate
- Tirzepatide's '3-Month Program' is listed at the identical $339/month as the month-to-month rate despite being advertised as '15% savings vs month-to-month' — a page inconsistency worth flagging before treating either figure as final
Medro
60/100Where the value is
- Live pricing tiers for both semaglutide and tirzepatide are transparent and fully disclosed (month-to-month through 12-month) without needing to enter the intake flow
- LegitScript-certified (seal #50716646, verified against legitscript.com) and available in all 50 states
- Named clinical partner (Arora Health & Aesthetics, LLC — Dr. Sean Arora, NPI 1841729449, Seattle, WA) and named compounding pharmacy (The Pharmacy Hub, Miami, FL) — both real, both verifiable, though neither is surfaced in the site's marketing copy
The tradeoffs
- The lowest advertised rate ($149 semaglutide / $224 tirzepatide) requires a full 12-month prepaid commitment; the no-commitment month-to-month rate is 33% higher ($199/$299)
- No mg dose is disclosed for any pricing tier — the plans are priced by commitment length only, so it's unclear what dose a given monthly price actually delivers
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.